BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, highvalue healthcare solutions for transplant patients and caregivers, today announced that pivotal clinical validation data from the ACROBAT study (NCT04635384) will be presented at the 2026 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®,. ...

Company Overview - Caris Life Sciences has a comprehensive oncology database with over 1,016,000 molecular profiles[5] - The company has a global presence with over 1,800 employees[7] - Caris has established a Precision Oncology Alliance (POA) with 99 leading cancer centers[5] Data and Technology - The company has profiled over 1 million cases in its genomic dataset[9] - Caris possesses over 627,000 whole exomes and 678,000 whole transcriptomes[9, 11] - The company has access to over 740,000 profiles with matched molecular data and clinical outcomes[11] Market Trends and Reach - Cancer centers are standardizing molecular profiling towards technology and service leaders[13] - Caris has a field-based team of approximately 250 and 50 MSLs serving over 6,000 oncologists in the US[18] - The company has integrated ordering locations in over 3,350 EHRs[18] Financial Performance - Caris achieved $281 million in revenue in Q4 2025, representing a 116% year-over-year growth[35, 67] - The company's total revenue increased to $800 million in FY 2025, a 94% increase year-over-year[69] - Molecular profiling services revenue increased to $755 million, a 116% increase year-over-year[69]

Core Viewpoint - CareDx, Inc. reported preliminary, unaudited financial results for the fourth quarter and full year 2025, highlighting significant revenue growth in the transplant healthcare sector [1]. Financial Performance - The company achieved revenue of approximately $108 million in the fourth quarter of 2025, representing a 25% increase year-over-year [1].

Core Insights - Tempus AI, Inc. is advancing the adoption of AI in precision medicine, particularly in gastrointestinal cancers [1] Group 1: Company Developments - Eight abstracts from Tempus have been accepted for presentation at the 2026 ASCO Gastrointestinal Cancers Symposium [1] - The symposium is scheduled to take place from January 8 to 10 in San Francisco, California [1] Group 2: Research Commitment - The research presented by Tempus at the ASCO GI symposium reflects the company's commitment to advancing progress in gastrointestinal cancers [1] - The presentations demonstrate the effectiveness of utilizing AI in cancer research [1]

Core Insights - Rune Labs has appointed Amy Gordon Franzen as the new Chief Executive Officer to lead the company's growth, particularly in expanding its AI platform StrivePD for neurological conditions beyond Parkinson's Disease [1][4] - The company aims to enhance its partnerships with clinicians, payers, and biopharma leaders to improve patient care and expand its commercial reach [3][5] Company Overview - Rune Labs specializes in precision medicine for neurology, utilizing advanced AI and FDA-cleared algorithms to support care delivery and therapy development [5] - The StrivePD platform, launched in 2022, has evolved into a comprehensive software ecosystem that facilitates remote care, AI-enabled symptom tracking, and real-world evidence generation for Parkinson's patients [3][5] Leadership Background - Amy Franzen previously held significant roles at Tempus, Groupon, Nike, and McKinsey & Company, where she focused on building partnerships and scaling clinical trial organizations [2] - Co-founder Brian Pepin will transition to President, Biopharma and Platform, to lead the expansion of Rune Labs' biopharma partnerships and research portfolio [1][3] Strategic Goals - The company plans to extend its AI-enabled care infrastructure to address a broader range of neurological conditions, including Alzheimer's disease and other forms of dementia [1][3] - Franzen emphasized the importance of scaling the commercial and clinical infrastructure to integrate more deeply with trial sponsors, payers, and health systems [5]

Core Viewpoint - CareDx, Inc. has announced a strategic collaboration with 10x Genomics to establish ImmuneScape, a multiomics research initiative aimed at enhancing healthcare solutions for transplant patients and caregivers [1] Group 1: Company Overview - CareDx, Inc. is a leading precision medicine company focused on the discovery, development, and commercialization of high-value healthcare solutions for transplant patients and caregivers [1] - 10x Genomics is recognized as a leader in single cell and spatial biology [1] Group 2: Strategic Collaboration - The collaboration between CareDx and 10x Genomics is aimed at establishing ImmuneScape, which is designed to elucidate complex biological systems [1]

Group 1 - Tempus AI, Inc. (NASDAQ:TEM) is recognized as a leading healthcare AI stock, with JPMorgan lowering its price target from $85 to $80 while maintaining a Neutral rating [1][2] - TD Cowen has reiterated a Hold rating on Tempus AI with an unchanged price target of $88, expressing optimism about the company's potential in pharmaceutical research and development efficiency [2][3] - TD Cowen is expanding its coverage on Tempus AI, focusing on the company's data infrastructure and the application of its AI-driven solutions in the healthcare sector [3] Group 2 - Tempus AI specializes in AI-enabled precision medicine, utilizing clinical and molecular data to enhance patient outcomes through machine learning and genomic sequencing [4]

Core Insights - BioNexus Gene Lab Corp. (BGLC) has entered into a $500,000,000 Equity Purchase Agreement with ARC Group International Ltd. to enhance its capital position for strategic initiatives [1][4] - The agreement allows BGLC to issue and sell registered shares of its common stock to ARC over a 36-month period, with a one-time fee of 175,000 shares issued at a price of $4.32 [2] - The facility complements BGLC's existing $20 million At-The-Market program, providing financial flexibility while maintaining control over capital deployment [3] Advancing Precision Oncology - BGLC has executed a licensing agreement with Fidelion Diagnostics to commercialize the VitaGuard™ MRD assay, aimed at early cancer detection and monitoring [5] - The new facility will support clinical adoption and infrastructure development for MRD testing across Southeast Asia, including Malaysia, Singapore, Indonesia, and Thailand [5] Supporting CDMO Transformation - BGLC is expanding into contract development and manufacturing organization (CDMO) services, enhancing its capabilities in biologics production and high-performance diagnostics [6] - The facility will enable investments in quality systems, manufacturing capacity, and strategic partnerships aligned with global CDMO standards [6] Advancing Therapeutic Opportunities - BGLC is progressing a strategic partnership with BirchBioMed Inc. for a therapeutic candidate targeting fibrosis and skin regeneration [7] - The facility provides capital optionality to support clinical and regulatory preparations as the partnership moves forward [7] Company Overview - BioNexus Gene Lab Corp. is focused on precision medical diagnostics and expanding into contract development and manufacturing services across Southeast Asia [9] - The company is headquartered in Kuala Lumpur, Malaysia, and aims to enhance its capabilities in oncology diagnostics and biologics development [9]

Core Insights - CareDx, Inc. is a leading precision medicine company focused on healthcare solutions for transplant patients and caregivers [1] Inducement Grants - On November 4, 2025, CareDx awarded restricted stock units (RSUs) to 49 new employees as an inducement for accepting employment [1]

Financial Performance - Total revenue increased to $216.8 million, a 113% year-over-year increase[10] - Molecular Profiling Services revenue increased to $207.6 million, a 121% year-over-year increase[10] - Pharma R&D Services revenue increased to $9.2 million, an 18% year-over-year increase[10] - Clinical ASP improved by 87%, from $2,184 to $4,089[13] - Achieved Positive Adjusted EBITDA of $51.2 million and GAAP Net Income of $24.3 million[13] - Achieved Positive Free Cash Flow of $55.3 million[13] - Q3 2025 gross margin was 68%, a ~2,432 bps improvement[13] Clinical Volume and Data - Clinical volume grew by 18%, completing 50,763 clinical cases[13] - The dataset surpassed 959,000+ genomic profiles and 660,000+ matched profiles including over 577,000 WES and 628,000 WTS[13] Guidance - Updated CY 2025 total revenue guidance to $720 - $730 million, representing 75-77% year-over-year growth[50] - Updated CY 2025 clinical therapy selection volume growth to 21-22% year-over-year[50] Partnership - 97 POA sites with now over 1,150 publications[13]